{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:40:04Z","timestamp":1779932404908,"version":"3.53.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11892-017-0893-0","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T08:26:54Z","timestamp":1500884814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?"],"prefix":"10.1007","volume":"17","author":[{"given":"Laura N.","family":"McEwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Stark","family":"Casagrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihchen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"893_CR1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/diaspect.27.2.82","volume":"27","author":"JR White Jr","year":"2014","unstructured":"White JR Jr. A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27:82\u20136.","journal-title":"Diabetes Spectr"},{"key":"893_CR2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"\u2022\u2022 Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858\u201371. This article reviews the origins and effects of high drug prices in the U.S. and discusses policy options that might control their cost.","journal-title":"JAMA"},{"key":"893_CR3","unstructured":"The RED BOOK Online Search-Micromedex Solutions; Micromedex 2.0, (electronic version). Truven Health Analytics, Greenwood Village. Available at: http:\/\/www.micromedexsolutions.com.proxy.lib.umich.edu \/ (cited: 08 May 2017)."},{"key":"893_CR4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJMms1411398","volume":"372","author":"JA Greene","year":"2015","unstructured":"Greene JA, Riggs KR. Why is there no generic insulin? Historical origins of a modern problem. N Engl J Med. 2015;372:1171\u20135.","journal-title":"N Engl J Med"},{"key":"893_CR5","first-page":"46","volume":"124","author":"JA Shayman","year":"2013","unstructured":"Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124:46\u201360.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"893_CR6","unstructured":"McEwen LN, Herman WH. Health care utilization and costs of diabetes. Chapter #40 in Diabetes in America, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. Bethesda, National Institutes of Health, NIH Pub No. 17\u20131468, 2017."},{"key":"893_CR7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2016.0126","volume":"315","author":"X Hua","year":"2016","unstructured":"\u2022 Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA. 2016;315:1400\u20132. This study reports trends in expenditures for different classes of antihyperglycemic medications in the U.S. that simultaneously consider changes in use and price.","journal-title":"JAMA"},{"key":"893_CR8","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1177\/1932296816658056","volume":"10","author":"AW Carter","year":"2016","unstructured":"\u2022 Carter AW, Heinemann L. If PBMs guard access to drugs, then quis custodiet ipsos custodies? (who will guard the guardians?). J Diabetes Sci Technol. 2016;10:1406\u201310. This commentary discusses the complex and seemingly obscure factors that drive insulin prices and discusses who benefits from higher drug prices.","journal-title":"J Diabetes Sci Technol"},{"key":"893_CR9","unstructured":"Thomas K. Drug makers accused of fixing prices on insulin. The New York Times. 2017. Available at: https:\/\/www.nytimes.com\/2017\/01\/30\/health\/drugmakers-lawsuit-insulin-drugs.html?_r=0 . Accessed 9 Feb 2017."},{"issue":"Suppl. 1","key":"893_CR10","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc17-S011","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(Suppl. 1):S64\u201374.","journal-title":"Diabetes Care"},{"key":"893_CR11","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854\u201365. Erratum in: Lancet 1998;352:1558.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"893_CR12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","volume":"316","author":"SC Palmer","year":"2016","unstructured":"Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316:313\u201324.","journal-title":"JAMA"},{"key":"893_CR13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"893_CR14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"893_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, LEADER Steering Committee, LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"893_CR16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, SUSTAIN-6 Investigators, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"893_CR17","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, et al., GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36:2254\u201361. GRADE is the first pragmatic, comparative effectiveness trial to compare commonly used glucose-lowering medications combined with metformin in patients with recently diagnosed type 2 diabetes. Its overarching goal is to provide better guidance to health care professionals on the choice of glucose-lowering medications.","DOI":"10.2337\/dc13-0356"},{"key":"893_CR18","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.289.17.2254","volume":"289","author":"DE DeWitt","year":"2003","unstructured":"DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254\u201364.","journal-title":"JAMA"},{"key":"893_CR19","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2337\/dc14-1140","volume":"37","author":"JL Chiang","year":"2014","unstructured":"Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034\u201354.","journal-title":"Diabetes Care"},{"key":"893_CR20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2337\/dc13-2915","volume":"37","author":"MB Davidson","year":"2014","unstructured":"Davidson MB. Insulin analogs\u2014is there a compelling case to use them? No! Diabetes Care. 2014;37:1771\u20134.","journal-title":"Diabetes Care"},{"key":"893_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7326\/M16-1847","volume":"166","author":"DM Blumenthal","year":"2017","unstructured":"\u2022 Blumenthal DM, Goldman DP, Jena AB. Outcomes-based pricing as a tool to ensure access to novel but expensive biopharmaceuticals. Ann Intern Med. 2017;166:219\u201320. This commentary proposes an outcomes-based drug pricing approach that uses real-world clinical outcomes to determine a drug\u2019s efficacy and fair market price. Manufacturers are paid on the basis of the drug\u2019s actual benefits.","journal-title":"Ann Intern Med"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-017-0893-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-017-0893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-017-0893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T13:31:06Z","timestamp":1569936666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-017-0893-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1007\/s11892-017-0893-0","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"article-number":"71"}}